References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2021-2-89-93

mrj-1128

Research Article

ОБЗОРЫ

REVIEWS

Перспективы применения ингибиторов фактора некроза опухоли α у больных COVID-19

The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19

https://orcid.org/0000-0002-1833-5357

Аронова

Е. С.

Aronova

E. S.

Евгения Сергеевна Аронова

115522, Москва, Каширское шоссе, 34А

Evgeniya Sergeevna Aronova

34A, Kashirskoe shosse, Moscow115522

eugpozd@mail.ru

https://orcid.org/0000-0001-7091-2054

Белов

Б. С.

Belov

B. S.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe shosse, Moscow115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation

2021

23042021

1528993

2021

Аронова Е.С., Белов Б.С.

Aronova E.S., Belov B.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/1128

Обзор посвящен проблеме поиска новых эффективных стратегий лечения коронавирусной болезни (COVID-19). Терапевтической мишенью может стать фактор некроза опухоли α (ФНОα). Приведены теоретические предпосылки успешного использования ингибиторов ФНОα (иФНОα) для лечения COVID-19, описан полученный за время эпидемии практический опыт применения препаратов этой группы, в том числе нашедший отражение в клинических исследованиях. В качестве возможных вариантов терапии рассматриваются два иФНОα – инфликсимаб и адалимумаб. Освещены вопросы безопасности иФНОα при лечении пациентов с иммуновоспалительными ревматическими заболеваниями и с COVID-19. Уделено внимание вакцинации против COVID-19, в частности имеющимся на данный момент в России вакцинам, находящимся на разных этапах клинических испытаний. Сделано заключение о необходимости проведения рандомизированных клинических исследований эффективности и безопасности применения иФНОα при новой коронавирусной инфекции, что позволит перейти от теоретических предпосылок к клинической практике.

The review highlights the problem of finding new effective treatment strategies for COVID-19. Tumor necrosis factor α (TNF-α) is considered as a therapeutic target. The theoretical basis for the successful use of TNF-α inhibitors (ITNFα) for the treatment of COVID-19 is presented, as well as data on existing practical developments, including ongoing clinical trials. Two drugs from the group of ITNFα – infliximab and adalimumab – are currently being considered as possible options. The safety issues of ITNFα treatment in patients with immunophaling rheumatic diseases and COVID-19 are discussed. The review also provides current data on vaccination against COVID-19, in particular on the vaccines currently available in Russia, which are at different stages of clinical trials. We conclude that randomized clinical trials of the effectiveness and safety of ITNF-α in patients with the new coronavirus infection are needed. Such trials will promote transition from theoretical speculations to real clinical practice.

коронавирусная инфекцияингибиторы фактора некроза опухоли αSARS-CoV-2COVID-19иммуновоспалительные ревматические заболеванияинфликсимабадалимумаб

the new coronavirus infectioninhibitors of tumor necrosing factor αSARS-COV-2COVID-19immunoinflammatory rheumatic diseasesinfliximabadalimumab

References1

Draft landscape of COVID-19 candidate vaccines. WHO (16.12.2020). https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.

Разрабатываемые и используемые в России вакцины. https://вакцина.стопкоронавирус.рф

Vaccines developed and used in Russia. https://вакцина.стопкоронавирус.рф

Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following antiTNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999 Aug 1;163(3):1521-8.

Paleolog EM, Young S, Stark AC, et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998 Jul;41(7):1258-65. doi: 10.1002/1529-0131(199807)41:73.0.CO;2-1.

Majewska E, Paleolog E, Baj Z, et al. Role of tyrosine kinase enzymes in TNF-alpha and IL-1 induced expression of ICAM-1 and VCAM-1 on human umbilical vein endothelial cells. Scand J Immunol. 1997 Apr;45(4): 385-92. doi: 10.1046/j.1365-3083.1997.d01-412.x.

Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001;19:163-96. doi: 10.1146/annurev.immunol.19.1.163.

Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995 May;146(5): 1029-39.

Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia. J Exp Med. 1989 Nov 1;170(5):1627-33. doi: 10.1084/jem.170.5.1627.

Haworth C, Brennan FM, Chantry D, et al. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol. 1991 Oct;21(10):2575-9. doi: 10.1002/eji.1830211039.

Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008 Sep;31(2):175-9. doi: 10.1016/j.jaut.2008.07.002. Epub 2008 Aug 15.

Del Valle DM, KimSchulze S, Huang H, et al. An inflammatory cytokine signature predicts COVID19 severity and survival. Nat Med. 2020 Oct;26(10):1636-43. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.

Lee JS, Park S, Jeong HW, et al. Immunophenotyping of COVID19 and influenza highlights the role of type I interferons in development of severe COVID19. Sci Immunol. 2020 Jul 10;5(49):eabd1554. doi: 10.1126/sciimmunol.abd1554.

Haga S, Yamamoto N, Nakai-Murakami C, et al. Modulation of TNF-a-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-a production and facilitates viral entry. Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14. doi: 10.1073/pnas.0711241105. Epub 2008 May 19.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.

Feldmann M, Maini RN, Woody JN, et al. Trials of antitumour necrosis factor therapy for COVID19 are urgently needed. Lancet. 2020 May 2;395(10234):1407-09. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.

Gianfrancesco M, Hyrich KL, Al-Adely S, et al; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859-66. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.

Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021 Jan;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007. Epub 2020 Oct 16.

Stallmach A, Kortgen A, Gonnert F, et al. Infliximab against severe COVID-19- induced cytokine storm syndrome with organ failure-a cautionary case series. Crit Care. 2020 Jul 17; 24(1):444. doi: 10.1186/s13054-020-03158-0.

Rodriguez-Lago I, Ramirez de la Piscina P, Elorza A, et al. Characteristics and prognosis of patients with inflammatory bowel disease during the SARS-CoV-2 pandemic in the Basque country (Spain). Gastroenterology. 2020 Aug;159(2):781-3. doi: 10.1053/j.gastro.2020.04.043. Epub 2020 Apr 21.

Waggershauser CH, Tillack-Schreiber C, Berchtold-Benchieb C, et al. Letter: immunotherapy in IBD patients in a SARSCoV- 2 endemic area. Aliment Pharmacol Ther. 2020 Sep;52(5):898-9. doi: 10.1111/apt.15897.

Winthrop KL, Brunton AE, Beekmann S, et al; COVID-19 Study Team. SARS CoV-2 infection among patients using immunomodulatory therapies. Ann Rheum Dis. 2021 Feb;80(2):269-71. doi: 10.1136/annrheumdis-2020-218580. Epub 2020 Aug 5.

Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network metaanalysis and Cochrane overview. Cochrane Database Syst Rev. 2011 Feb 16;2011(2): CD008794. doi: 10.1002/14651858.CD008794.pub2.

Rutherford AI, Subesinghe S, Hyrich KL, Galloway JB. Serious infection across biologictreated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018 Jun;77(6):905-10. doi: 10.1136/annrheumdis2017-212825. Epub 2018 Mar 28.

Аронова ЕС, Лукина ГВ, Сигидин ЯА. Переносимость инфликсимаба у пациентов с ревматоидным артритом в реальной клинической практике. Научно-практическая ревматология. 2020; 58(1):31-6.

Aronova ES, Lukina GV, Sigidin YaA. The tolerability of infliximab in patients with rheumatoid arthritis in real clinical practice. Nauchno-prakticheskaya revmatologiya. 2020; 58(1):31-6. (In Russ.).

Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995 Mar 22-29;273(12):934-41.

Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996 Sep;24(9):1431-40. doi: 10.1097/00003246-199609000-00002.

Li X, Andersen KM, Chang HY, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis. 2020 Feb; 79(2):285-91. doi: 10.1136/annrheumdis2019-216102. Epub 2019 Oct 31.

Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020 Aug;159(2): 481-91.e3. doi: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18.

Nurmohamed M, Bao Y, Signorovitch J, et al. Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015 May 21;1(1):e000080. doi: 10.1136/rmdopen2015-000080. eCollection 2015.

Greenberg JD, Kremer JM, Curtis JR, et al; CORRONA Investigators. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Apr;70(4):576-82. doi: 10.1136/ard.2010.129916. Epub 2010 Nov 24.

Komaki F, Komaki Y, Micic D, et al. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-a use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun. 2017 Jan;76:38-52. doi: 10.1016/j.jaut.2016.11.004. Epub 2016 Nov 30.

Clowse M, Forger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017 Nov;76(11):1890-6. doi: 10.1136/annrheumdis-2017-211384. Epub 2017 Aug 16.

Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018 Feb;77(2): 228-33. doi: 10.1136/annrheumdis-2017-212196. Epub 2017 Oct 13.

Esfahani K, Elkrief A, Calabrese C, et al. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020 Aug;17(8):504-15. doi: 10.1038/s41571-020-0352-8. Epub 2020 Apr 3.

Robinson PC, Liew DF, Liew JW, et al. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med (N Y). 2020 Dec 18;1(1):90-102. doi: 10.1016/j.medj.2020.11.005. Epub 2020 Dec 3.

D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ’hot spot’. Ann Rheum Dis. 2020 Sep;79(9):1156-162. doi: 10.1136/annrheumdis-2020-217888. Epub 2020 May 26.

ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04593940

ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04425538?term=infliximab&cond=covid&draw=2&rank=1 (accessed Jun 19 2020).

Chinese Trial Clinical Registry. A randomized, open-label, controlled trial for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19) (ChiCTR2000030089). http://www.chictr.org.cn/showprojen.aspx?proj=49889

Mahase E. Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community. BMJ. 2020 Oct 1;371:m3847. doi: 10.1136/bmj.m3847.

McCann F, Shepard HM, Feldmann M. Treating cytokine storms in COVID-19 patients. 23 Oct 2020. https://www.drugtargetreview.com/article/74674/treating-cytokinestorms-in-covid-19-patients.

McCann FE, Perocheau DP, Ruspi G, et al. Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. Arthritis Rheumatol. 2014 Oct;66(10):2728-38. doi: 10.1002/art.38755.

Tseng WY, Huang YS, Clanchy F, et al. TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells. Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21666-72. doi: 10.1073/pnas.1909687116. Epub 2019 Oct 9.

Meckiff BJ, Ramirez-Suastegui C, Fajardo V, et al. Imbalance of regulatory and cytotoxic SARS-CoV-2-reactive CD4+ T cells in COVID-19. Cell 2020 Nov 25; 183(5):1340-53.e16. doi: 10.1016/j.cell.2020.10.001.

The authors declare that there are no conflicts of interest present.